- Home
- NTRA
NTRA
Natera Inc.
as 04-18-2025 1:40pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 18.4B | IPO Year: | 2015 |
| Target Price: | $176.65 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $83.13 - $183.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,696,911,000 | Revenue Growth: | 56.75% |
| Revenue Growth (this year): | 15.33% | Revenue Growth (next year): | 18.50% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sheena Jonathan | NTRA | Director | Apr 3 '25 | Sell | $137.43 | 6,070 | $826,326.90 | 40,282 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Apr 1 '25 | Sell | $140.79 | 3,000 | $421,428.19 | 142,221 | |
| Marcus Gail Boxer | NTRA | Director | Apr 1 '25 | Sell | $141.14 | 4,000 | $563,100.30 | 13,306 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Mar 28 '25 | Sell | $138.40 | 1,404 | $194,326.94 | 225,281 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Mar 28 '25 | Sell | $138.39 | 2,562 | $354,603.27 | 75,557 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Mar 28 '25 | Sell | $139.97 | 25,461 | $3,556,947.64 | 196,643 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Mar 17 '25 | Sell | $147.88 | 1,026 | $149,835.56 | 142,221 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Mar 17 '25 | Sell | $147.88 | 928 | $135,521.13 | 225,281 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Mar 17 '25 | Sell | $147.80 | 795 | $116,099.12 | 157,289 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Mar 17 '25 | Sell | $147.80 | 792 | $115,661.03 | 75,557 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a day ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Simply Wall St.
3 days ago
3 Top Stocks Estimated To Trade At Up To 48.4% Below Intrinsic Value
StockStory
4 days ago
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Simply Wall St.
5 days ago
High Growth Tech Stocks In US With Potential For Expansion
StockStory
5 days ago
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Simply Wall St.
7 days ago
Natera (NasdaqGS:NTRA) Climbs 11% in One Week
Simply Wall St.
9 days ago
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?
Insider Monkey
11 days ago
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.